Cellyan Biotechnology (HKPD) Receivables (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Receivables of $5.8 million for Q3 2025, up 20.55% year-over-year from $4.8 million in Q3 2024, and up 22.41% quarter-over-quarter from $4.7 million in Q1 2025.
Cellyan Biotechnology (HKPD) Receivables (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Receivables for 2 consecutive years, with $5.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Receivables rose 20.55% year-over-year to $5.8 million; the TTM figure through Sep 2025 stood at $5.8 million (up 20.55% YoY), while the FY2025 annual figure was $5.1 million, up 2.88% from the prior year.
- Receivables rose to $5.8 million in Q3 2025 per HKPD's latest filing, from $4.7 million in the prior quarter.
- Across five years, Receivables topped out at $5.8 million in Q3 2025 and bottomed at $3.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.64 Bn | 97.48 Bn | 3.69 Bn | 30.32 Bn |
| 2 | Cencora | 61.42 Bn | 58.60 Bn | 3.61 Bn | 25.45 Bn |
| 3 | Cardinal Health | 54.18 Bn | 49.32 Bn | 2.56 Bn | 13.82 Bn |
| 4 | Henry Schein | 10.03 Bn | 9.87 Bn | 1.10 Bn | 1.79 Bn |
| 5 | Akso Health | 676.38 Mn | 676.18 Mn | - | 193.81 Mn |
| 6 | Edap Tms | 155.55 Mn | 134.01 Mn | 7.34 Mn | 12.25 Mn |
| 7 | Accendra Health | 92.42 Mn | 84.77 Mn | 263.41 Mn | 120.08 Mn |
| 8 | 111 | 30.17 Mn | -28.59 Mn | 18.18 Mn | 27.28 Mn |
| 9 | Cosmos Health | 13.08 Mn | 10.63 Mn | 1.51 Mn | 22.44 Mn |
| 10 | Cellyan Biotechnology | 6.38 Mn | 6.16 Mn | - | 3.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.80 Mn |
| Sep 30, 2025 | 5.77 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Mar 31, 2024 | 3.72 Mn |